LENZ Therapeutics Reports Q2 2026 Earnings with Revenue Growth and Strategic Expansion
LENZ Therapeutics (LENZ) reported second-quarter results for fiscal year 2026, highlighting revenue growth driven by both product sales and international licensing milestones. Total revenue reached $5.5 million, including a regulatory milestone payment from Canada and sublicensing fees in Greater China. The company noted strong prescription growth of over 45% in July, attributed to the launch of its telehealth platform and national advertising campaign. LENZ also reported high patient persistence rates—over 60% through its ePharmacy channel—and an annualized purchase rate of five monthly packs per patient based on early data. The company has secured international commercialization agreements across multiple regions, with nine regulatory submissions under review globally. Despite a net loss of $31.9 million for the quarter, LENZ maintains strong cash reserves of $220 million to support its ongoing expansion and marketing efforts.
Tickers: $LENZ
Topics: financial_performance licensing_agreements prescription_growth product_sales revenue